The evaluation of the cytotoxic activity of the NK cells was also evaluated by measuring the plasma levels of granzyme A and B. No significant differences were observed when the levels of both granzymes in the COVID-19 patients were compared to the healthy controls (Table S2) or when the patients were divided according to disease severity (Figure S5A,B). This evidence concerns the gene GZMA and COVID-19.